Recombinant monoclonal antibody to CD4. Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease and multiple sclerosis but has not yet received U.S. Food and Drug Administration licencing.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Priliximab.
Afuco™ Anti-CD4 ADCC Therapeutic Antibody (Priliximab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD4. Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody.
For research use only. Not intended for any clinical use.